


LISTING OF CLAIMS

- 1 - (presently amended)

A method-of-treating a living animal for inhibition of progression or alleviation of a condition which is alleviated by a $5HT_3$ or neuronal nicotinic receptor antagonist, selected from emesis, cerebellar tremor, [and] appetite disorders, and irritable bowel syndrome comprising the step of administering to the said living animal an amount of a 1-aminoalkylcyclohexane compound selected from the group consisting of those of the formula



wherein R^* is $-(CH_2)_n-(CR^6R^7)_m-NR^8R^9$

wherein $n+m = 0, 1, \text{ or } 2$

wherein R^1 through R^7 are independently selected from the group consisting of hydrogen and lower-alkyl C_1-C_6 , wherein R^8 and R^9 are independently selected from the group consisting of hydrogen and lower-alkyl C_1-C_6 or together represent lower-alkylene $-(CH_2)_x-$ wherein x is 2 to 5, inclusive, and optical isomers, enantiomers, hydrates, and pharmaceutically-acceptable salts thereof, which is effective for the said purpose.

- 2 - (previously presented)

A method of Claim 1 wherein at least R^1 , R^4 , and R^5 are lower-alkyl.

- 3 - (previously presented)

A method of Claim 2 wherein R^1 through R^5 are methyl.

- 4 - (previously presented)

A method of Claim 1 wherein R¹ is ethyl.

- 5 - (previously presented)

A method of Claim 1 wherein R² is ethyl.

- 6 - (previously presented)

A method of Claim 1 wherein R³ is ethyl.

- 7 - (previously presented)

A method of Claim 1 wherein R⁴ is ethyl.

- 8 - (previously presented)

A method of Claim 1 wherein R⁵ is ethyl.

- 9 - (previously presented)

A method of Claim 1 wherein R⁵ is propyl.

- 10 - (previously presented)

A method of Claim 1 wherein R⁶ or R⁷ is methyl.

- 11 - (previously presented)

A method of Claim 1 wherein R⁶ or R⁷ is ethyl.

- 12 - (previously presented)

A method of Claim 2 wherein X is 4 or 5.

- 13 - (previously presented)

A method of Claim 3 wherein X is 4 or 5.

- 14 - (previously cancelled)

- 15 - (previously presented)

A method of Claim 1 wherein the compound is selected from the group consisting of

1-Amino-1,3,3,5,5-pentamethylcyclohexane,

1-Amino-1-propyl-3,3,5,5-tetramethylcyclohexane,

1-Amino-1,3,3,5(trans)-tetramethylcyclohexane (axial amino group),

1-Amino-1,3,5,5-tetramethyl-3-ethylcyclohexane (mixture of diastereomers),

1-Amino-1,3,5-trimethylcyclohexane (mixture of diastereomers),
1-Amino-1,3-dimethyl-3-propylcyclohexane (mixture of diastereomers),
1-Amino-1,3 (trans),5 (trans)-trimethyl-3(cis)- propylcyclohexane,
1-Amino-1,3-dimethyl-3-ethylcyclohexane,
1-Amino-1,3,3-trimethylcyclohexane,
1-Amino-1,3 (trans)-dimethylcyclohexane,
1-Amino-1-methyl-3 (trans) propylcyclohexane,
1-Amino-1-methyl-3 (trans) ethylcyclohexane,
1-Amino-1,3,3-trimethyl-5 (cis) ethylcyclohexane,
1-Amino-1,3,3-trimethyl-5 (trans) ethylcyclohexane,
N-methyl-1-Amino-1,3,3,5,5-pentamethylcyclohexane,
1-Amino-1-methylcyclohexane,
N,N-dimethyl-1-amino-1,3,3,5,5-pentamethylcyclohexane,
1-Amino-1,5,5-trimethyl-3(cis)-isopropyl-cyclohexane,
1-Amino-1,5,5-trimethyl-3(trans)-isopropyl-cyclohexane,
1-Amino-1-methyl-3(cis)-ethyl-cyclohexane,
1-Amino-1-methyl-3(cis)-methyl-cyclohexane,
1-Amino-5,5-diethyl-1,3,3-trimethyl-cyclohexane, and
N-(1,3,3,5,5-pentamethylcyclohexyl) pyrrolidine,
and optical isomers, enantiomers, hydrates and pharmaceutically-acceptable salts of any of the foregoing.

- 16 - (previously presented)

A method of Claim 1 wherein the compound is administered in the form of a pharmaceutical composition thereof comprising the compound in combination with one or more pharmaceutically-acceptable diluents, excipients, or carriers.

- 17 - (previously presented)

A method of Claim 15 wherein the compound is administered in the form of a pharmaceutical composition thereof comprising the compound in combination with one or more pharmaceutically-acceptable diluents, excipients, or carriers.